Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir



Status:Completed
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:7/4/2018
Start Date:April 18, 2012
End Date:December 16, 2013

Use our guide to learn which trials are right for you!

A Phase III Randomized, Double-blind Study to Demonstrate the Antiviral Activity of Dolutegravir (DTG) 50 mg Twice Daily Versus Placebo Both Co-Administered With a Failing Antiretroviral Regimen Over Seven Days, Followed by an Open Label Phase With All Subjects Receiving DTG 50 mg Twice Daily Co-administered With an Optimised Background Regimen (OBR) in HIV-1 Infected, Integrase Inhibitor Therapy-Experienced and Resistant, Adults

Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo-
controlled, functional monotherapy phase to quantify the antiviral activity attributable to
dolutegravir (DTG) in HIV-1 infected, ART-experienced adults who are experiencing virological
failure on an Integrase inhibitor containing regimen (current RAL or ELV failures), with
evidence of genotypic resistance to RAL or ELV at study entry. Thirty subjects will be
randomized (1:1) to receive either DTG 50mg BID (Arm A) or Placebo (Arm B) with the current
failing regimen for 7 days (RAL or ELV should be discontinued prior to dosing with DTG). At
Day 8, subjects from both arms will enter an open label phase and receive open label DTG 50mg
BID with an optimized background regimen containing at least one fully active drug.

Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo-controlled,
functional monotherapy phase to assess the antiviral activity and safety of a dolutegravir
(DTG, GSK1349572) containing regimen in HIV-1 infected, ART-experienced adults with
virological failure on an integrase inhibitor (INI) containing regimen.

Subjects must have evidence of genotypic resistance to raltegravir [RAL] or elvitegravir
[ELV] at Screening and documented current or historical genotypic or phenotypic resistance to
at least two other antiretroviral therapy drug classes.

The study is designed to provide an accurate measure of the intrinsic antiviral activity of
DTG 50mg twice daily versus placebo both administered with the current failing regimen in a
randomised double-blind phase to Day 8. This will be followed by an open label phase with all
subjects receiving DTG 50mg twice daily with an optimized background regimen (containing at
least one fully active drug) until subjects no longer derive clinical benefit or until DTG is
locally available. Thirty subjects will be randomized (1:1) to receive either DTG 50mg BID
(Arm A) or Placebo (Arm B) with the current failing regimen for 7 days (RAL or ELV should be
discontinued prior to dosing at Day 1). At Day 8, subjects from both arms will enter an open
label phase and receive open label DTG 50mg BID with an optimized background regimen
containing at least one fully active drug The primary analysis will be conducted after the
last subject enrolled has completed the randomised, double-blind phase at Day 8. Additional
analyses may be performed prior to study closure when all ongoing subjects transition to
locally available commercial DTG.

Inclusion Criteria:

- Screening plasma HIV-1 RNA ≥1000 copies/mL

- ART-experienced, INI-experienced, DTG naïve

- Current virological failure on raltegravir (RAL) or elvitegravir (ELV) regimen

- The subject's HIV-1 shows genotypic resistance to RAL or ELV at Screening

- Subject has been on stable ART for at least one month prior to Screening and through
Day 1(with exceptions for ETV, EFV and NVP that can be interrupted within 14 days of
Day 1, see Exclusion Criterion)

- Documented resistance to at least one drug from each of two or more of any approved
classes of ART other than integrase inhibitors

- Be able to receive at least one fully active drug as part of the OBR from Day 8

- Women capable of becoming pregnant must use appropriate contraception during the study
(as defined by the protocol)

- Willing and able to understand and provide signed and dated written informed consent
prior to Screening.

Exclusion Criteria:

- Women who are pregnant or breast feeding

- An active AIDS-defining condition at Screening (except cutaneous Kaposi's sarcoma not
requiring systemic therapy or CD4+ <200c/mm3)

- Moderate to severe hepatic impairment as defined by Child-Pugh classification

- Anticipated need for HCV therapy during the first 24 weeks of the study

- Recent history (less than or equal to 3 months) of any upper or lower gastrointestinal
bleed, with the exception of anal or rectal bleeding

- Allergy or intolerance to the study drugs or their components or drugs of their class

- Malignancy within the past 6 months

- Treatment with an HIV-1 therapeutic vaccine within 90 days of Screening

- Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any
immunomodulator within 28 days of Screening

- Treatment with any agent, other than licensed ART, with documented in vitro/vivo
activity against HIV-1 within 28 days of first dose of investigational product (with
the exception of entecavir if required for Hep B treatment)

- Treatment with etravirine, efavirenz, or nevirapine within 14 days of Day 1(etravirine
may be used if coadministered with lopinavir/ritonavir or darunavir/ritonavir)

- Treatment with tipranivir/ritonavir, fosamprenavir, or fosamprenavir/ritonavir within
28 days prior to Screening

- Exposure to an experimental drug or vaccine within either 28 days, 5 half-lives of the
test agent, or twice the duration of the biological effect of the test agent, which
ever is longer, prior to the first dose of IP.

- Any acute or verified Grade 4 laboratory abnormality (with the exception of Grade 4
lipids) at Screening

- ALT> 5 times the upper limit of normal (ULN) at Screening

- ALT ≥ 3X ULN and bilirubin > 1.5 X ULN (with 35% direct bilirubin) at Screening
We found this trial at
24
sites
Buffalo, New York 14263
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Annandale, Virginia 22003
?
mi
from
Annandale, VA
Click here to add this to my saved trials
Augusta, Georgia 30909
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Austin, Texas 78705
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bakersfield, California 93309
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Boston, Massachusetts 02115
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bronx, New York 10461
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Dallas, Texas 75230
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fort Lauderdale, Florida 33308
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Fort Pierce, Florida 34982
?
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
Hillsborough, New Jersey 08844
?
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
Little Rock, Arkansas 72205
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Los Angeles, California 90025
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Maywood, Illinois 60153
?
mi
from
Maywood, IL
Click here to add this to my saved trials
New York, New York 10032
?
mi
from
New York, NY
Click here to add this to my saved trials
Norwalk, Connecticut 06850
?
mi
from
Norwalk, CT
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
San Diego, California 92111
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Savannah, Georgia 31405
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Valhalla, New York 10595
?
mi
from
Valhalla, NY
Click here to add this to my saved trials
Washington, District of Columbia 20007
?
mi
from
Washington,
Click here to add this to my saved trials